Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Biologics

PUBLISHER: Fairfield Market Research | PRODUCT CODE: 1591716

Cover Image

PUBLISHER: Fairfield Market Research | PRODUCT CODE: 1591716

Biologics Contract Manufacturing Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031

PUBLISHED:
PAGES: 185 Pages
DELIVERY TIME: 2-5 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF & Excel (Single User License)
USD 4995
Unprintable PDF & Excel (Multi User License upto 5 users)
USD 8495
Printable PDF & Excel (Enterprise License above 5 users)
USD 10600

Add to Cart

Description

Table of Contents

The global biologics contract manufacturing market is poised for significant growth, with worldwide revenue expected to grow from USD 16.01 billion in 2024 to a substantial USD 36.3 billion by 2031. Projected to expand at a CAGR of 12.4%, this market reflects an increased demand for novel biologic and biosimilar products, especially as companies embrace contract manufacturing to streamline R&D and commercialization processes.

The biologics contract manufacturing market is driven by the expansion of the biopharmaceutical contract manufacturing organization (CMO) sector. Consolidation efforts are underway, with market participants adopting inorganic growth strategies and developing end-to-end integrated solutions that offer clients comprehensive services. Biopharmaceutical CMOs with advanced technological capabilities are uniquely positioned to capitalize on this burgeoning market, bolstered by rapid scientific advancements in the field.

Drivers of Market Growth

1.Growing Demand for Biologics and Biosimilars: The need for innovative biologics and biosimilars is expanding, spurring demand for contract manufacturing services.

2.R&D Outsourcing: Companies increasingly rely on CMOs and CDMOs (contract development and manufacturing organizations) to optimize R&D expenditures, enhancing operational efficiency.

3.Scientific and Technological Advancements: Innovations in biopharmaceutical manufacturing, such as single-use bioreactors and cell & gene therapy capabilities, are propelling market growth. Notable examples include Lonza Group AG's acquisition of a Shire plc facility, enhancing their mammalian manufacturing operations, and AGC Biologics' acquisition of Molecular Medicine S.p.A. to strengthen its gene therapy capabilities.

Business Opportunities

The CDMO business model is evolving to support high potency drug development and biopharmaceuticals, offering a range of product options that drive competitive differentiation. By outsourcing stages of clinical development to strategic partners, companies can achieve greater efficiencies across the value chain. Furthermore, as CMOs and CDMOs optimize manufacturing technologies, they are also creating opportunities for long-term profitability through cost-effective and scalable solutions.

Region Analysis

  • United States: In North America, the U.S. holds a leading position, capturing approximately 89.9% of the market in 2023. Strong pipelines for biologics, high venture capital investment in biotechnology R&D, and a growing presence of prominent manufacturers and research institutions contribute to the U.S. market's strength.
  • Germany: Holding around 33.7% of the European market share in 2023, Germany is emerging as a lucrative market. Increasing biopharmaceutical research and clinical trials drive demand, with many companies outsourcing their research activities to reduce costs.
  • China: China commands an 18.2% market share within East Asia, driven by collaborations between global and local firms. As pharmaceutical and biopharmaceutical companies increase their presence in China, they unlock opportunities for contract manufacturing growth over the forecast period.

Impact of Regulatory Dynamics

The biologics contract manufacturing market faces some challenges due to shifting regulatory policies, cGMP compliance requirements, and complex supply chain security issues in emerging countries. Entry barriers are high for small and medium enterprises (SMEs) due to substantial financial requirements. Additionally, many countries face a shortage of skilled professionals and adequate funding, slowing the development of a robust biotech industry similar to that in the U.S.

Competitive Analysis

Leading companies are focusing on expanding their service portfolios and establishing a presence in emerging markets to capitalize on growth potential. Major players in the biologics contract manufacturing market include:

  • BioXcellence (Boehringer Ingelheim)
  • Lonza Group AG
  • Samsung Biologics
  • Fujifilm Diosynth Biotechnologies
  • AbbVie CM (AbbVie Inc.)
  • WuXi Biologics (Cayman) Inc.
  • AGC Biologics
  • Patheon N.V. (Thermo Fisher Scientific Inc.)
  • Emergent BioSolutions Inc.
  • Ajinomoto Bio-Pharma
  • Avid Bioservices, Inc.
  • KBI Biopharma
  • Rentschler Biotechnologie GmbH
  • Merck KGaA
  • Catalent Inc.
  • Therapure Biopharma Inc.
  • Novasep
  • Abzena plc.
  • ProBioGen AG

Biologics Contract Manufacturing Market Segmentation

The biologics contract manufacturing market is segmented as follows:

Product:

  • Monoclonal Antibodies
  • Recombinant Proteins
  • Vaccines
  • Insulin
  • Interferons
  • Growth Factors
  • Others

Platform:

  • Mammalian
  • Microbial

Therapeutic Area:

  • Oncology
  • Autoimmune Disease
  • Metabolic Disease
  • Ophthalmology
  • Cardiovascular Disease
  • Infectious Disease
  • Neurology
  • Respiratory Disorder
  • Others

Application:

  • Commercial
  • Clinical

Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa
Show more

Table of Contents

1. Executive Summary

  • 1.1. Global Biologics Contract Manufacturing Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value and Volume, 2024
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. Porter's Five Forces Analysis
  • 2.5. COVID-19 Impact Analysis
    • 2.5.1. Supply
    • 2.5.2. Demand
  • 2.6. Impact of Ukraine-Russia Conflict
  • 2.7. Economic Overview
    • 2.7.1. World Economic Projections
  • 2.8. PESTLE Analysis

3. Price Analysis, 2018 - 2023

  • 3.1. Global Average Price Analysis, by Product/ Platform, US$ Per Unit, 2018 - 2023
  • 3.2. Prominent Factor Affecting Biologics Contract Manufacturing Prices
  • 3.3. Global Average Price Analysis, by Region, US$ Per Unit

4. Global Biologics Contract Manufacturing Market Outlook, 2019-2031

  • 4.1. Global Biologics Contract Manufacturing Market Outlook, by Product, Value (US$ Bn) and Volume (KL), 2019-2031
    • 4.1.1. Key Highlights
      • 4.1.1.1. Monoclonal Antibodies
      • 4.1.1.2. Recombinant Proteins
      • 4.1.1.3. Vaccines
      • 4.1.1.4. Insulin
      • 4.1.1.5. Interferons
      • 4.1.1.6. Growth Factors
      • 4.1.1.7. Others
  • 4.2. Global Biologics Contract Manufacturing Market Outlook, by Platform, Value (US$ Bn) and Volume (KL), 2019-2031
    • 4.2.1. Key Highlights
      • 4.2.1.1. Mammalian
      • 4.2.1.2. Microbial
  • 4.3. Global Biologics Contract Manufacturing Market Outlook, by Therapeutic Area, Value (US$ Bn) and Volume (KL), 2019-2031
    • 4.3.1. Key Highlights
      • 4.3.1.1. Oncology
      • 4.3.1.2. Autoimmune Disease
      • 4.3.1.3. Metabolic Disease
      • 4.3.1.4. Ophthalmology
      • 4.3.1.5. Cardiovascular Disease
      • 4.3.1.6. Infectious Disease
      • 4.3.1.7. Neurology
      • 4.3.1.8. Respiratory Disorder
      • 4.3.1.9. Others
  • 4.4. Global Biologics Contract Manufacturing Market Outlook, by Application, Value (US$ Bn) and Volume (KL), 2019-2031
    • 4.4.1. Key Highlights
      • 4.4.1.1. Commercial
      • 4.4.1.2. Clinical
  • 4.5. Global Biologics Contract Manufacturing Market Outlook, by Region, Value (US$ Bn) and Volume (KL), 2019-2031
    • 4.5.1. Key Highlights
      • 4.5.1.1. North America
      • 4.5.1.2. Europe
      • 4.5.1.3. Asia Pacific
      • 4.5.1.4. Latin America
      • 4.5.1.5. Middle East & Africa

5. North America Biologics Contract Manufacturing Market Outlook, 2019-2031

  • 5.1. North America Biologics Contract Manufacturing Market Outlook, by Product, Value (US$ Bn) and Volume (KL), 2019-2031
    • 5.1.1. Key Highlights
      • 5.1.1.1. Monoclonal Antibodies
      • 5.1.1.2. Recombinant Proteins
      • 5.1.1.3. Vaccines
      • 5.1.1.4. Insulin
      • 5.1.1.5. Interferons
      • 5.1.1.6. Growth Factors
      • 5.1.1.7. Others
  • 5.2. North America Biologics Contract Manufacturing Market Outlook, by Platform, Value (US$ Bn) and Volume (KL), 2019-2031
    • 5.2.1. Key Highlights
      • 5.2.1.1. Mammalian
      • 5.2.1.2. Microbial
  • 5.3. North America Biologics Contract Manufacturing Market Outlook, by Therapeutic Area, Value (US$ Bn) and Volume (KL), 2019-2031
    • 5.3.1. Key Highlights
      • 5.3.1.1. Oncology
      • 5.3.1.2. Autoimmune Disease
      • 5.3.1.3. Metabolic Disease
      • 5.3.1.4. Ophthalmology
      • 5.3.1.5. Cardiovascular Disease
      • 5.3.1.6. Infectious Disease
      • 5.3.1.7. Neurology
      • 5.3.1.8. Respiratory Disorder
      • 5.3.1.9. Others
  • 5.4. North America Biologics Contract Manufacturing Market Outlook, by Application, Value (US$ Bn) and Volume (KL), 2019-2031
    • 5.4.1. Key Highlights
      • 5.4.1.1. Commercial
      • 5.4.1.2. Clinical
  • 5.5. North America Biologics Contract Manufacturing Market Outlook, by Country, Value (US$ Bn) and Volume (KL), 2019-2031
    • 5.5.1. Key Highlights
      • 5.5.1.1. U.S. Biologics Contract Manufacturing Market by Product, Value (US$ Bn) and Volume (KL), 2019-2031
      • 5.5.1.2. U.S. Biologics Contract Manufacturing Market by Platform, Value (US$ Bn) and Volume (KL), 2019-2031
      • 5.5.1.3. U.S. Biologics Contract Manufacturing Market by Therapeutic Area, Value (US$ Bn) and Volume (KL), 2019-2031
      • 5.5.1.4. U.S. Biologics Contract Manufacturing Market by Application, Value (US$ Bn) and Volume (KL), 2019-2031
      • 5.5.1.5. Canada Biologics Contract Manufacturing Market by Product, Value (US$ Bn) and Volume (KL), 2019-2031
      • 5.5.1.6. Canada Biologics Contract Manufacturing Market by Platform, Value (US$ Bn) and Volume (KL), 2019-2031
      • 5.5.1.7. Canada Biologics Contract Manufacturing Market by Therapeutic Area, Value (US$ Bn) and Volume (KL), 2019-2031
      • 5.5.1.8. Canada Biologics Contract Manufacturing Market by Application, Value (US$ Bn) and Volume (KL), 2019-2031
    • 5.5.2. BPS Analysis/Market Attractiveness Analysis

6. Europe Biologics Contract Manufacturing Market Outlook, 2019-2031

  • 6.1. Europe Biologics Contract Manufacturing Market Outlook, by Product, Value (US$ Bn) and Volume (KL), 2019-2031
    • 6.1.1. Key Highlights
      • 6.1.1.1. Monoclonal Antibodies
      • 6.1.1.2. Recombinant Proteins
      • 6.1.1.3. Vaccines
      • 6.1.1.4. Insulin
      • 6.1.1.5. Interferons
      • 6.1.1.6. Growth Factors
      • 6.1.1.7. Others
  • 6.2. Europe Biologics Contract Manufacturing Market Outlook, by Platform, Value (US$ Bn) and Volume (KL), 2019-2031
    • 6.2.1. Key Highlights
      • 6.2.1.1. Mammalian
      • 6.2.1.2. Microbial
  • 6.3. Europe Biologics Contract Manufacturing Market Outlook, by Therapeutic Area, Value (US$ Bn) and Volume (KL), 2019-2031
    • 6.3.1. Key Highlights
      • 6.3.1.1. Oncology
      • 6.3.1.2. Autoimmune Disease
      • 6.3.1.3. Metabolic Disease
      • 6.3.1.4. Ophthalmology
      • 6.3.1.5. Cardiovascular Disease
      • 6.3.1.6. Infectious Disease
      • 6.3.1.7. Neurology
      • 6.3.1.8. Respiratory Disorder
      • 6.3.1.9. Others
  • 6.4. Europe Biologics Contract Manufacturing Market Outlook, by Application, Value (US$ Bn) and Volume (KL), 2019-2031
    • 6.4.1. Key Highlights
      • 6.4.1.1. Commercial
      • 6.4.1.2. Clinical
  • 6.5. Europe Biologics Contract Manufacturing Market Outlook, by Country, Value (US$ Bn) and Volume (KL), 2019-2031
    • 6.5.1. Key Highlights
      • 6.5.1.1. Germany Biologics Contract Manufacturing Market by Product, Value (US$ Bn) and Volume (KL), 2019-2031
      • 6.5.1.2. Germany Biologics Contract Manufacturing Market by Platform, Value (US$ Bn) and Volume (KL), 2019-2031
      • 6.5.1.3. Germany Biologics Contract Manufacturing Market by Therapeutic Area, Value (US$ Bn) and Volume (KL), 2019-2031
      • 6.5.1.4. Germany Biologics Contract Manufacturing Market by Application, Value (US$ Bn) and Volume (KL), 2019-2031
      • 6.5.1.5. U.K. Biologics Contract Manufacturing Market by Product, Value (US$ Bn) and Volume (KL), 2019-2031
      • 6.5.1.6. U.K. Biologics Contract Manufacturing Market by Platform, Value (US$ Bn) and Volume (KL), 2019-2031
      • 6.5.1.7. U.K. Biologics Contract Manufacturing Market by Therapeutic Area, Value (US$ Bn) and Volume (KL), 2019-2031
      • 6.5.1.8. U.K. Biologics Contract Manufacturing Market by Application, Value (US$ Bn) and Volume (KL), 2019-2031
      • 6.5.1.9. France Biologics Contract Manufacturing Market by Product, Value (US$ Bn) and Volume (KL), 2019-2031
      • 6.5.1.10. France Biologics Contract Manufacturing Market by Platform, Value (US$ Bn) and Volume (KL), 2019-2031
      • 6.5.1.11. France Biologics Contract Manufacturing Market by Therapeutic Area, Value (US$ Bn) and Volume (KL), 2019-2031
      • 6.5.1.12. France Biologics Contract Manufacturing Market by Application, Value (US$ Bn) and Volume (KL), 2019-2031
      • 6.5.1.13. Italy Biologics Contract Manufacturing Market by Product, Value (US$ Bn) and Volume (KL), 2019-2031
      • 6.5.1.14. Italy Biologics Contract Manufacturing Market by Platform, Value (US$ Bn) and Volume (KL), 2019-2031
      • 6.5.1.15. Italy Biologics Contract Manufacturing Market by Therapeutic Area, Value (US$ Bn) and Volume (KL), 2019-2031
      • 6.5.1.16. Italy Biologics Contract Manufacturing Market by Application, Value (US$ Bn) and Volume (KL), 2019-2031
      • 6.5.1.17. Turkey Biologics Contract Manufacturing Market by Product, Value (US$ Bn) and Volume (KL), 2019-2031
      • 6.5.1.18. Turkey Biologics Contract Manufacturing Market by Platform, Value (US$ Bn) and Volume (KL), 2019-2031
      • 6.5.1.19. Turkey Biologics Contract Manufacturing Market by Therapeutic Area, Value (US$ Bn) and Volume (KL), 2019-2031
      • 6.5.1.20. Turkey Biologics Contract Manufacturing Market by Application, Value (US$ Bn) and Volume (KL), 2019-2031
      • 6.5.1.21. Russia Biologics Contract Manufacturing Market by Product, Value (US$ Bn) and Volume (KL), 2019-2031
      • 6.5.1.22. Russia Biologics Contract Manufacturing Market by Platform, Value (US$ Bn) and Volume (KL), 2019-2031
      • 6.5.1.23. Russia Biologics Contract Manufacturing Market by Therapeutic Area, Value (US$ Bn) and Volume (KL), 2019-2031
      • 6.5.1.24. Russia Biologics Contract Manufacturing Market by Application, Value (US$ Bn) and Volume (KL), 2019-2031
      • 6.5.1.25. Rest of Europe Biologics Contract Manufacturing Market by Product, Value (US$ Bn) and Volume (KL), 2019-2031
      • 6.5.1.26. Rest of Europe Biologics Contract Manufacturing Market by Platform, Value (US$ Bn) and Volume (KL), 2019-2031
      • 6.5.1.27. Rest of Europe Biologics Contract Manufacturing Market by Therapeutic Area, Value (US$ Bn) and Volume (KL), 2019-2031
      • 6.5.1.28. Rest of Europe Biologics Contract Manufacturing Market by Application, Value (US$ Bn) and Volume (KL), 2019-2031
    • 6.5.2. BPS Analysis/Market Attractiveness Analysis

7. Asia Pacific Biologics Contract Manufacturing Market Outlook, 2019-2031

  • 7.1. Asia Pacific Biologics Contract Manufacturing Market Outlook, by Product, Value (US$ Bn) and Volume (KL), 2019-2031
    • 7.1.1. Key Highlights
      • 7.1.1.1. Monoclonal Antibodies
      • 7.1.1.2. Recombinant Proteins
      • 7.1.1.3. Vaccines
      • 7.1.1.4. Insulin
      • 7.1.1.5. Interferons
      • 7.1.1.6. Growth Factors
      • 7.1.1.7. Others
  • 7.2. Asia Pacific Biologics Contract Manufacturing Market Outlook, by Platform, Value (US$ Bn) and Volume (KL), 2019-2031
    • 7.2.1. Key Highlights
      • 7.2.1.1. Mammalian
      • 7.2.1.2. Microbial
  • 7.3. Asia Pacific Biologics Contract Manufacturing Market Outlook, by Therapeutic Area, Value (US$ Bn) and Volume (KL), 2019-2031
    • 7.3.1. Key Highlights
      • 7.3.1.1. Oncology
      • 7.3.1.2. Autoimmune Disease
      • 7.3.1.3. Metabolic Disease
      • 7.3.1.4. Ophthalmology
      • 7.3.1.5. Cardiovascular Disease
      • 7.3.1.6. Infectious Disease
      • 7.3.1.7. Neurology
      • 7.3.1.8. Respiratory Disorder
      • 7.3.1.9. Others
  • 7.4. Asia Pacific Biologics Contract Manufacturing Market Outlook, by Application, Value (US$ Bn) and Volume (KL), 2019-2031
    • 7.4.1. Key Highlights
      • 7.4.1.1. Commercial
      • 7.4.1.2. Clinical
  • 7.5. Asia Pacific Biologics Contract Manufacturing Market Outlook, by Country, Value (US$ Bn) and Volume (KL), 2019-2031
    • 7.5.1. Key Highlights
      • 7.5.1.1. China Biologics Contract Manufacturing Market by Product, Value (US$ Bn) and Volume (KL), 2019-2031
      • 7.5.1.2. China Biologics Contract Manufacturing Market by Platform, Value (US$ Bn) and Volume (KL), 2019-2031
      • 7.5.1.3. China Biologics Contract Manufacturing Market by Therapeutic Area, Value (US$ Bn) and Volume (KL), 2019-2031
      • 7.5.1.4. China Biologics Contract Manufacturing Market by Application, Value (US$ Bn) and Volume (KL), 2019-2031
      • 7.5.1.5. Japan Biologics Contract Manufacturing Market by Product, Value (US$ Bn) and Volume (KL), 2019-2031
      • 7.5.1.6. Japan Biologics Contract Manufacturing Market by Platform, Value (US$ Bn) and Volume (KL), 2019-2031
      • 7.5.1.7. Japan Biologics Contract Manufacturing Market by Therapeutic Area, Value (US$ Bn) and Volume (KL), 2019-2031
      • 7.5.1.8. Japan Biologics Contract Manufacturing Market by Application, Value (US$ Bn) and Volume (KL), 2019-2031
      • 7.5.1.9. South Korea Biologics Contract Manufacturing Market by Product, Value (US$ Bn) and Volume (KL), 2019-2031
      • 7.5.1.10. South Korea Biologics Contract Manufacturing Market by Platform, Value (US$ Bn) and Volume (KL), 2019-2031
      • 7.5.1.11. South Korea Biologics Contract Manufacturing Market by Therapeutic Area, Value (US$ Bn) and Volume (KL), 2019-2031
      • 7.5.1.12. South Korea Biologics Contract Manufacturing Market by Application, Value (US$ Bn) and Volume (KL), 2019-2031
      • 7.5.1.13. India Biologics Contract Manufacturing Market by Product, Value (US$ Bn) and Volume (KL), 2019-2031
      • 7.5.1.14. India Biologics Contract Manufacturing Market by Platform, Value (US$ Bn) and Volume (KL), 2019-2031
      • 7.5.1.15. India Biologics Contract Manufacturing Market by Therapeutic Area, Value (US$ Bn) and Volume (KL), 2019-2031
      • 7.5.1.16. India Biologics Contract Manufacturing Market by Application, Value (US$ Bn) and Volume (KL), 2019-2031
      • 7.5.1.17. Southeast Asia Biologics Contract Manufacturing Market by Product, Value (US$ Bn) and Volume (KL), 2019-2031
      • 7.5.1.18. Southeast Asia Biologics Contract Manufacturing Market by Platform, Value (US$ Bn) and Volume (KL), 2019-2031
      • 7.5.1.19. Southeast Asia Biologics Contract Manufacturing Market by Therapeutic Area, Value (US$ Bn) and Volume (KL), 2019-2031
      • 7.5.1.20. Southeast Asia Biologics Contract Manufacturing Market by Application, Value (US$ Bn) and Volume (KL), 2019-2031
      • 7.5.1.21. Rest of Asia Pacific Biologics Contract Manufacturing Market by Product, Value (US$ Bn) and Volume (KL), 2019-2031
      • 7.5.1.22. Rest of Asia Pacific Biologics Contract Manufacturing Market by Platform, Value (US$ Bn) and Volume (KL), 2019-2031
      • 7.5.1.23. Rest of Asia Pacific Biologics Contract Manufacturing Market by Therapeutic Area, Value (US$ Bn) and Volume (KL), 2019-2031
      • 7.5.1.24. Rest of Asia Pacific Biologics Contract Manufacturing Market by Application, Value (US$ Bn) and Volume (KL), 2019-2031
    • 7.5.2. BPS Analysis/Market Attractiveness Analysis

8. Latin America Biologics Contract Manufacturing Market Outlook, 2019-2031

  • 8.1. Latin America Biologics Contract Manufacturing Market Outlook, by Product, Value (US$ Bn) and Volume (KL), 2019-2031
    • 8.1.1. Key Highlights
      • 8.1.1.1. Monoclonal Antibodies
      • 8.1.1.2. Recombinant Proteins
      • 8.1.1.3. Vaccines
      • 8.1.1.4. Insulin
      • 8.1.1.5. Interferons
      • 8.1.1.6. Growth Factors
      • 8.1.1.7. Others
  • 8.2. Latin America Biologics Contract Manufacturing Market Outlook, by Platform, Value (US$ Bn) and Volume (KL), 2019-2031
    • 8.2.1. Key Highlights
      • 8.2.1.1. Mammalian
      • 8.2.1.2. Microbial
  • 8.3. Latin America Biologics Contract Manufacturing Market Outlook, by Therapeutic Area, Value (US$ Bn) and Volume (KL), 2019-2031
    • 8.3.1. Key Highlights
      • 8.3.1.1. Oncology
      • 8.3.1.2. Autoimmune Disease
      • 8.3.1.3. Metabolic Disease
      • 8.3.1.4. Ophthalmology
      • 8.3.1.5. Cardiovascular Disease
      • 8.3.1.6. Infectious Disease
      • 8.3.1.7. Neurology
      • 8.3.1.8. Respiratory Disorder
      • 8.3.1.9. Others
  • 8.4. Latin America Biologics Contract Manufacturing Market Outlook, by Application, Value (US$ Bn) and Volume (KL), 2019-2031
    • 8.4.1. Key Highlights
      • 8.4.1.1. Commercial
      • 8.4.1.2. Clinical
  • 8.5. Latin America Biologics Contract Manufacturing Market Outlook, by Country, Value (US$ Bn) and Volume (KL), 2019-2031
    • 8.5.1. Key Highlights
      • 8.5.1.1. Brazil Biologics Contract Manufacturing Market by Product, Value (US$ Bn) and Volume (KL), 2019-2031
      • 8.5.1.2. Brazil Biologics Contract Manufacturing Market by Platform, Value (US$ Bn) and Volume (KL), 2019-2031
      • 8.5.1.3. Brazil Biologics Contract Manufacturing Market by Therapeutic Area, Value (US$ Bn) and Volume (KL), 2019-2031
      • 8.5.1.4. Brazil Biologics Contract Manufacturing Market by Application, Value (US$ Bn) and Volume (KL), 2019-2031
      • 8.5.1.5. Mexico Biologics Contract Manufacturing Market by Product, Value (US$ Bn) and Volume (KL), 2019-2031
      • 8.5.1.6. Mexico Biologics Contract Manufacturing Market by Platform, Value (US$ Bn) and Volume (KL), 2019-2031
      • 8.5.1.7. Mexico Biologics Contract Manufacturing Market by Therapeutic Area, Value (US$ Bn) and Volume (KL), 2019-2031
      • 8.5.1.8. Mexico Biologics Contract Manufacturing Market by Application, Value (US$ Bn) and Volume (KL), 2019-2031
      • 8.5.1.9. Argentina Biologics Contract Manufacturing Market by Product, Value (US$ Bn) and Volume (KL), 2019-2031
      • 8.5.1.10. Argentina Biologics Contract Manufacturing Market by Platform, Value (US$ Bn) and Volume (KL), 2019-2031
      • 8.5.1.11. Argentina Biologics Contract Manufacturing Market by Therapeutic Area, Value (US$ Bn) and Volume (KL), 2019-2031
      • 8.5.1.12. Argentina Biologics Contract Manufacturing Market by Application, Value (US$ Bn) and Volume (KL), 2019-2031
      • 8.5.1.13. Rest of Latin America Biologics Contract Manufacturing Market by Product, Value (US$ Bn) and Volume (KL), 2019-2031
      • 8.5.1.14. Rest of Latin America Biologics Contract Manufacturing Market by Platform, Value (US$ Bn) and Volume (KL), 2019-2031
      • 8.5.1.15. Rest of Latin America Biologics Contract Manufacturing Market by Therapeutic Area, Value (US$ Bn) and Volume (KL), 2019-2031
      • 8.5.1.16. Rest of Latin America Biologics Contract Manufacturing Market by Application, Value (US$ Bn) and Volume (KL), 2019-2031
    • 8.5.2. BPS Analysis/Market Attractiveness Analysis

9. Middle East & Africa Biologics Contract Manufacturing Market Outlook, 2019-2031

  • 9.1. Middle East & Africa Biologics Contract Manufacturing Market Outlook, by Product, Value (US$ Bn) and Volume (KL), 2019-2031
    • 9.1.1. Key Highlights
      • 9.1.1.1. Monoclonal Antibodies
      • 9.1.1.2. Recombinant Proteins
      • 9.1.1.3. Vaccines
      • 9.1.1.4. Insulin
      • 9.1.1.5. Interferons
      • 9.1.1.6. Growth Factors
      • 9.1.1.7. Others
  • 9.2. Middle East & Africa Biologics Contract Manufacturing Market Outlook, by Platform, Value (US$ Bn) and Volume (KL), 2019-2031
    • 9.2.1. Key Highlights
      • 9.2.1.1. Mammalian
      • 9.2.1.2. Microbial
  • 9.3. Middle East & Africa Biologics Contract Manufacturing Market Outlook, by Therapeutic Area, Value (US$ Bn) and Volume (KL), 2019-2031
    • 9.3.1. Key Highlights
      • 9.3.1.1. Oncology
      • 9.3.1.2. Autoimmune Disease
      • 9.3.1.3. Metabolic Disease
      • 9.3.1.4. Ophthalmology
      • 9.3.1.5. Cardiovascular Disease
      • 9.3.1.6. Infectious Disease
      • 9.3.1.7. Neurology
      • 9.3.1.8. Respiratory Disorder
      • 9.3.1.9. Others
  • 9.4. Middle East & Africa Biologics Contract Manufacturing Market Outlook, by Application, Value (US$ Bn) and Volume (KL), 2019-2031
    • 9.4.1. Key Highlights
      • 9.4.1.1. Commercial
      • 9.4.1.2. Clinical
  • 9.5. Middle East & Africa Biologics Contract Manufacturing Market Outlook, by Country, Value (US$ Bn) and Volume (KL), 2019-2031
    • 9.5.1. Key Highlights
      • 9.5.1.1. GCC Biologics Contract Manufacturing Market by Product, Value (US$ Bn) and Volume (KL), 2019-2031
      • 9.5.1.2. GCC Biologics Contract Manufacturing Market by Platform, Value (US$ Bn) and Volume (KL), 2019-2031
      • 9.5.1.3. GCC Biologics Contract Manufacturing Market by Therapeutic Area, Value (US$ Bn) and Volume (KL), 2019-2031
      • 9.5.1.4. GCC Biologics Contract Manufacturing Market by Application, Value (US$ Bn) and Volume (KL), 2019-2031
      • 9.5.1.5. South Africa Biologics Contract Manufacturing Market by Product, Value (US$ Bn) and Volume (KL), 2019-2031
      • 9.5.1.6. South Africa Biologics Contract Manufacturing Market by Platform, Value (US$ Bn) and Volume (KL), 2019-2031
      • 9.5.1.7. South Africa Biologics Contract Manufacturing Market by Therapeutic Area, Value (US$ Bn) and Volume (KL), 2019-2031
      • 9.5.1.8. South Africa Biologics Contract Manufacturing Market by Application, Value (US$ Bn) and Volume (KL), 2019-2031
      • 9.5.1.9. Egypt Biologics Contract Manufacturing Market by Product, Value (US$ Bn) and Volume (KL), 2019-2031
      • 9.5.1.10. Egypt Biologics Contract Manufacturing Market by Platform, Value (US$ Bn) and Volume (KL), 2019-2031
      • 9.5.1.11. Egypt Biologics Contract Manufacturing Market by Therapeutic Area, Value (US$ Bn) and Volume (KL), 2019-2031
      • 9.5.1.12. Egypt Biologics Contract Manufacturing Market by Application, Value (US$ Bn) and Volume (KL), 2019-2031
      • 9.5.1.13. Nigeria Biologics Contract Manufacturing Market by Product, Value (US$ Bn) and Volume (KL), 2019-2031
      • 9.5.1.14. Nigeria Biologics Contract Manufacturing Market by Platform, Value (US$ Bn) and Volume (KL), 2019-2031
      • 9.5.1.15. Nigeria Biologics Contract Manufacturing Market by Therapeutic Area, Value (US$ Bn) and Volume (KL), 2019-2031
      • 9.5.1.16. Nigeria Biologics Contract Manufacturing Market by Application, Value (US$ Bn) and Volume (KL), 2019-2031
      • 9.5.1.17. Rest of Middle East & Africa Biologics Contract Manufacturing Market by Product, Value (US$ Bn) and Volume (KL), 2019-2031
      • 9.5.1.18. Rest of Middle East & Africa Biologics Contract Manufacturing Market by Platform, Value (US$ Bn) and Volume (KL), 2019-2031
      • 9.5.1.19. Rest of Middle East & Africa Biologics Contract Manufacturing Market by Therapeutic Area, Value (US$ Bn) and Volume (KL), 2019-2031
      • 9.5.1.20. Rest of Middle East & Africa Biologics Contract Manufacturing Market by Application, Value (US$ Bn) and Volume (KL), 2019-2031
    • 9.5.2. BPS Analysis/Market Attractiveness Analysis

10. Competitive Landscape

  • 10.1. Product vs Platform Heatmap
  • 10.2. Competitive Dashboard
  • 10.3. Company Profiles
    • 10.3.1. BioXcellence (Boehringer Ingelheim)
      • 10.3.1.1. Company Overview
      • 10.3.1.2. Product Portfolio
      • 10.3.1.3. Financial Overview
      • 10.3.1.4. Business Strategies and Development
    • 10.3.2. Lonza Group AG
      • 10.3.2.1. Company Overview
      • 10.3.2.2. Product Portfolio
      • 10.3.2.3. Financial Overview
      • 10.3.2.4. Business Strategies and Development
    • 10.3.3. Samsung Biologics
      • 10.3.3.1. Company Overview
      • 10.3.3.2. Product Portfolio
      • 10.3.3.3. Financial Overview
      • 10.3.3.4. Business Strategies and Development
    • 10.3.4. Fujifilm Diosynth Biotechnologies
      • 10.3.4.1. Company Overview
      • 10.3.4.2. Product Portfolio
      • 10.3.4.3. Financial Overview
      • 10.3.4.4. Business Strategies and Development
    • 10.3.5. AbbVie CM (AbbVie Inc.)
      • 10.3.5.1. Company Overview
      • 10.3.5.2. Product Portfolio
      • 10.3.5.3. Financial Overview
      • 10.3.5.4. Business Strategies and Development
    • 10.3.6. WuXi Biologics (Cayman) Inc.
      • 10.3.6.1. Company Overview
      • 10.3.6.2. Product Portfolio
      • 10.3.6.3. Financial Overview
      • 10.3.6.4. Business Strategies and Development
    • 10.3.7. AGC Biologics
      • 10.3.7.1. Company Overview
      • 10.3.7.2. Product Portfolio
      • 10.3.7.3. Financial Overview
      • 10.3.7.4. Business Strategies and Development
    • 10.3.8. Patheon N.V. (Thermo Fisher Scientific Inc.)
      • 10.3.8.1. Company Overview
      • 10.3.8.2. Product Portfolio
      • 10.3.8.3. Financial Overview
      • 10.3.8.4. Business Strategies and Development
    • 10.3.9. Emergent BioSolutions Inc.
      • 10.3.9.1. Company Overview
      • 10.3.9.2. Product Portfolio
      • 10.3.9.3. Financial Overview
      • 10.3.9.4. Business Strategies and Development
    • 10.3.10. Ajinomoto Bio-Pharma
      • 10.3.10.1. Company Overview
      • 10.3.10.2. Product Portfolio
      • 10.3.10.3. Financial Overview
      • 10.3.10.4. Business Strategies and Development
    • 10.3.11. Avid Bioservices, Inc.
      • 10.3.11.1. Company Overview
      • 10.3.11.2. Product Portfolio
      • 10.3.11.3. Financial Overview
      • 10.3.11.4. Business Strategies and Development
    • 10.3.12. KBI Biopharma
      • 10.3.12.1. Company Overview
      • 10.3.12.2. Product Portfolio
      • 10.3.12.3. Financial Overview
      • 10.3.12.4. Business Strategies and Development
    • 10.3.13. Rentschler Biotechnologie GmbH
      • 10.3.13.1. Company Overview
      • 10.3.13.2. Product Portfolio
      • 10.3.13.3. Financial Overview
      • 10.3.13.4. Business Strategies and Development
    • 10.3.14. Merck KGaA
      • 10.3.14.1. Company Overview
      • 10.3.14.2. Product Portfolio
      • 10.3.14.3. Financial Overview
      • 10.3.14.4. Business Strategies and Development
    • 10.3.15. Catalent Inc.
      • 10.3.15.1. Company Overview
      • 10.3.15.2. Product Portfolio
      • 10.3.15.3. Financial Overview
      • 10.3.15.4. Business Strategies and Development
    • 10.3.16. Therapure Biopharma Inc.
      • 10.3.16.1. Company Overview
      • 10.3.16.2. Product Portfolio
      • 10.3.16.3. Financial Overview
      • 10.3.16.4. Business Strategies and Development
    • 10.3.17. Novasep
      • 10.3.17.1. Company Overview
      • 10.3.17.2. Product Portfolio
      • 10.3.17.3. Financial Overview
      • 10.3.17.4. Business Strategies and Development
    • 10.3.18. Abzena plc.
      • 10.3.18.1. Company Overview
      • 10.3.18.2. Product Portfolio
      • 10.3.18.3. Financial Overview
      • 10.3.18.4. Business Strategies and Development
    • 10.3.19. ProBioGen AG
      • 10.3.19.1. Company Overview
      • 10.3.19.2. Product Portfolio
      • 10.3.19.3. Financial Overview
      • 10.3.19.4. Business Strategies and Development

11. Appendix

  • 11.1. Research Methodology
  • 11.2. Report Assumptions
  • 11.3. Acronyms and Abbreviations
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!